Corebridge Financial’s Standard BioTools LAB Stock Holding History

Corebridge Financial’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-144,511	Closed	-$156K	–	1480
2025 Q1	$156K	Sell	144,511 -2,143	-1%	-$3.01K	﹤0.01%	2218
2024 Q4	$257K	Sell	146,654 -11,070	-7%	-$20.6K	﹤0.01%	2027
2024 Q3	$304K	Sell	157,724 -4,588	-3%	-$8.98K	﹤0.01%	1984
2024 Q2	$289K	Buy	+162,312	New	+$397K	﹤0.01%	1983

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Corebridge Financial's LAB Position: Q2 2025 in Review

Corebridge Financial sold out of Standard BioTools (LAB) in Q2 2025, closing a stake of 144,511 shares — an estimated $156K sold.

Corebridge Financial first reported a position in LAB in Q2 2024 and held it in 4 quarters. The position peaked at $304K in Q3 2024. 160 funds tracked by Wall St. Rank hold LAB as of Q2 2025.

Corebridge Financial reported no remaining Standard BioTools position as of Q2 2025 after selling out during the quarter.
Corebridge Financial sold 144,511 Standard BioTools shares in Q2 2025, an estimated $156K.
Corebridge Financial first reported a position in Standard BioTools in Q2 2024 and held it in 4 quarters.
Corebridge Financial's Standard BioTools position peaked at $304K in Q3 2024.
160 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.